(S)-1-(3-(N-(4-(3-phenylisoxazol-5-yl)thiazol-2-yl)thiophene-2-carboxamido)propyl)piperidine-2-carboxamide | 1006872-57-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-1-(3-(N-(4-(3-phenylisoxazol-5-yl)thiazol-2-yl)thiophene-2-carboxamido)propyl)piperidine-2-carboxamide
• 英文别名: (2S)-1-[3-[[4-(3-phenyl-1,2-oxazol-5-yl)-1,3-thiazol-2-yl]-(thiophene-2-carbonyl)amino]propyl]piperidine-2-carboxamide
• CAS: 1006872-57-6
• 化学式: C₂₆H₂₇N₅O₃S₂
• 分子量: 521.664
• InChiKey: CUJSUDWNNKJAKG-NRFANRHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  162
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (S)-1-(3-(N-(4-(3-phenylisoxazol-5-yl)thiazol-2-yl)thiophene-2-carboxamido)propyl)piperidine-2-carboxamide 在 盐酸 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 0.5h， 生成 (S)-1-(3-(N-(4-(3-phenylisoxazol-5-yl)thiazol-2-yl)thiophene-2-carboxamido)propyl)piperidine-2-carboxamide hydrochloride
  参考文献：
  名称：

  WO2008/22002

  摘要：

  公开号：
• 作为产物：
  描述：

  N-(3,3-二乙氧基丙基)-N-(4-(3-苯基异恶唑-5-基)噻唑-2-基)噻吩-2-甲酰胺 在 盐酸 、 溶剂黄146 作用下， 以 1,4-二氧六环 、 乙醚 、 1,2-二氯乙烷 为溶剂， 反应 1.67h， 生成 (S)-1-(3-(N-(4-(3-phenylisoxazol-5-yl)thiazol-2-yl)thiophene-2-carboxamido)propyl)piperidine-2-carboxamide
  参考文献：
  名称：

  WO2008/22002

  摘要：

  公开号：

文献信息

• 2-AMIDO-4-ISOXAZOLYL THIAZOLE COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF
  申请人：Dickson John K.

  公开号：US20080242709A1

  公开（公告）日：2008-10-02

  2-Amido-4-isoxazolyl thiazole compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed.

  本发明揭示了表现出ATP利用酶抑制活性的2-氨基-4-异噁唑基噻唑化合物，使用表现出ATP利用酶抑制活性的化合物的方法，以及包含表现出ATP利用酶抑制活性的化合物的组合物。
• PREDICTIVE BIOMARKERS FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY
  申请人：Genentech, Inc.

  公开号：US20130059859A1

  公开（公告）日：2013-03-07

  A method of predicting the sensitivity of tumor cell growth to inhibition by a PI3K/AKT kinase pathway inhibitor, comprising: determining the localization profile of FOXO3a in a tumor cell, wherein a cytoplasmic localization profile of FOXO3a correlates with sensitivity to inhibition by a PI3K/AKT kinase inhibitor and a nuclear localization profile of FOXO3a correlates with resistance to inhibition by a PI3K/AKT kinase inhibitor.
• AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS
  申请人：Lin Kiu

  公开号：US20140004209A1

  公开（公告）日：2014-01-02

  The subject matter disclosed herein relates to agents and methods of treating neoplasms with an agent that is a kinase inhibitor and is also an inducer of autophagy in combination with an agent that is an inhibitor of autophagy.
• BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS
  申请人：Lin Kui

  公开号：US20140031259A1

  公开（公告）日：2014-01-30

  Methods for predicting sensitivity to cancer treatments by assessing biomarkers and combinations of biomarkers include evaluating the presence of mutations to Akt, wherein the presence of said mutations correlates with the sensitivity of Akt inhibitors.
• METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DRUG RESISTANT AKT MUTANT
  申请人：GENENTECH, INC.

  公开号：US20160153049A1

  公开（公告）日：2016-06-02

  Methods for identifying or diagnosing AKT inhibitor resistant cancers and methods an compositions for treating.